Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2014 from OUS - The Lipid Clinic

10 publications found

Berge KE, Retterstøl K, Romeo S, Pirazzi C, Leren TP (2014)
Type 1 hyperlipoproteinemia due to a novel deletion of exons 3 and 4 in the GPIHBP1 gene
Atherosclerosis, 234 (1), 30-3
DOI 10.1016/j.atherosclerosis.2014.02.005, PubMed 24589565

Holven KB, Narverud I, Lindvig HW, Halvorsen B, Langslet G, Nenseter MS, Ulven SM, Ose L, Aukrust P, Retterstøl K (2014)
Subjects with familial hypercholesterolemia are characterized by an inflammatory phenotype despite long-term intensive cholesterol lowering treatment
Atherosclerosis, 233 (2), 561-7
DOI 10.1016/j.atherosclerosis.2014.01.022, PubMed 24530965

Kastelein JJ, Robinson JG, Farnier M, Krempf M, Langslet G, Lorenzato C, Gipe DA, Baccara-Dinet MT (2014)
Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies
Cardiovasc Drugs Ther, 28 (3), 281-9
DOI 10.1007/s10557-014-6523-z, PubMed 24842558

Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA, Millington D, Vercruysse F, Canovatchel W, Meininger G (2014)
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study
Diabetes Care, 38 (3), 355-64
DOI 10.2337/dc13-2762, PubMed 25205142

Mundal L, Sarancic M, Ose L, Iversen PO, Borgan JK, Veierød MB, Leren TP, Retterstøl K (2014)
Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992-2010
J Am Heart Assoc, 3 (6), e001236
DOI 10.1161/JAHA.114.001236, PubMed 25468658

Narverud I, Retterstøl K, Iversen PO, Halvorsen B, Ueland T, Ulven SM, Ose L, Aukrust P, Veierød MB, Holven KB (2014)
Markers of atherosclerotic development in children with familial hypercholesterolemia: a literature review
Atherosclerosis, 235 (2), 299-309
DOI 10.1016/j.atherosclerosis.2014.05.917, PubMed 24908240

Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, Blom D, Eriksson M, Dent R, Wasserman SM, Huang F, Xue A, Albizem M, Scott R, Stein EA (2014)
Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials
J Am Coll Cardiol, 63 (13), 1278-1288
DOI 10.1016/j.jacc.2014.01.006, PubMed 24509273

Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Scott R, Wasserman SM, Gaudet D, RUTHERFORD-2 Investigators (2014)
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
Lancet, 385 (9965), 331-40
DOI 10.1016/S0140-6736(14)61399-4, PubMed 25282519

Sjouke B, Langslet G, Ceska R, Nicholls SJ, Nissen SE, Öhlander M, Ladenson PW, Olsson AG, Hovingh GK, Kastelein JJ (2014)
Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study
Lancet Diabetes Endocrinol, 2 (6), 455-63
DOI 10.1016/S2213-8587(14)70006-3, PubMed 24731671

Versmissen J, Oosterveer DM, Yazdanpanah M, Dehghan A, Hólm H, Erdman J, Aulchenko YS, Thorleifsson G, Schunkert H, Huijgen R, Vongpromek R, Uitterlinden AG, Defesche JC, van Duijn CM, Mulder M, Dadd T, Karlsson HD, Ordovas J, Kindt I, Jarman A, Hofman A, van Vark-van der Zee L, Blommesteijn-Touw AC, Kwekkeboom J, Liem AH et al. (2014)
Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach
Eur J Hum Genet, 23 (3), 381-7
DOI 10.1038/ejhg.2014.101, PubMed 24916650

 
Page visits: 71063